Innohep

tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as an injectable solution for subcutaneous use. It is used to prevent and treat venous thromboembolism in adult patients.

GNH USA supplies Innohep as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Innohep (tinzaparin sodium) is used in the anticoagulation pathway to manage thrombotic disorders.

- Prevention of venous thromboembolism: reduces the risk of clot formation in patients undergoing surgery or immobilisation. - Treatment of deep vein thrombosis: facilitates clot resolution and prevents extension of the thrombus. - Treatment of pulmonary embolism: helps dissolve emboli and lowers the chance of recurrence.

Common Side Effects: - Injection site pain or bruising: mild discomfort at the subcutaneous site. - Minor bleeding: such as gum or nosebleeds. - Nausea or headache: transient and usually self‑limiting. - Elevated liver enzymes: occasional mild laboratory abnormality.

Serious or Rare Side Effects: - Major bleeding: gastrointestinal, intracranial or surgical site hemorrhage. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop with paradoxical clot risk. - Severe allergic reaction: rash, angioedema or anaphylaxis. - Spinal or epidural hematoma: rare but critical when neuraxial procedures are performed.

Innohep requires careful clinical monitoring to minimise risks.

- Assess renal function: dose adjustment may be needed in severe renal impairment. - Monitor platelet count: watch for heparin‑induced thrombocytopenia. - Evaluate bleeding risk: avoid in patients with active or uncontrolled bleeding. - Use caution with concurrent anticoagulants or antiplatelet agents. - Contraindicated in known hypersensitivity to tinzaparin or heparin products. - Store at ambient temperature: keep in original container, protect from moisture and light.

Innohep can interact with several medicines that affect haemostasis.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct oral anticoagulants): additive bleeding risk. - Antiplatelet agents (aspirin, clopidogrel): increased hemorrhage potential. - Fibrinolytic therapy (tPA, streptokinase): synergistic anticoagulant effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened gastrointestinal bleeding. - Neuraxial anesthesia or spinal puncture: risk of spinal hematoma.

Moderate Interactions (Monitor Closely): - Concurrent heparin therapy: cumulative anticoagulant effect. - Certain antibiotics (e.g., quinolones, macrolides): may potentiate bleeding. - Selective serotonin reuptake inhibitors (SSRIs) and corticosteroids: modest increase in bleeding tendency.